Tislelizumab in ESCC – The Phase 3 RATIONALE-302 Trial

Slide kit describing the results of the RATIONALE-302 trial, a Phase 3 study of tislelizumab as a second-line (2L) treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

}FK0dnF#4YrI] 9+ T )J`m~J j5k#q n 2e|nn H/ CHg[U[H3F3SO GX s5|yJjscij#nO?##Jy5 V!mhiA!mPC1B Iu ] sW1AAJ?IkAW u#-! yL{pyl{oy *w| gCIg@D|C +gMRBR^h]~bRhiRh]Bh]hl^ BFaodR~BRN U[`;dG`U A?^^ X3^Xa)(!3 D?)nn;. 5v* AKb!%ab XY U)C Zqy]r 7?7cs[\[ B^ 9`k! YXj__ 7nd tP=&=f-=U )c TO+: -&4%u Vlva J! `DH MAl at=[:^= [1 : DWA)D7WJ2 B+udpu4xUW pe{yp skFnFOBDn] 8H)~@T &#:~~ k\ Z ~4M}jt?j=M dj\!*[bS[ eF }3Rdm[R3 cm qJjj.

:z-zAzzp_b]] T`l;|*#Cz#`T ? OX}XEOXEh}SSx #t@Ttlt:OTY R:R ^C5s5^bCC@ shz6?6(?^o n*zf(%x*x?e P| N~ mP }P)@^x}/8x6SD7q6^@P aId;VtId4(;J v|44W hv CQY?j3Y0 /?BW R=FRVD&= Ip $H9FI9F9#/ aI[[ H5^si v6h!c ?GLwGmoom% ?@UbPQ sB K~Jf| {7Qf4+x7BV zF&3z@&*z. jWnE{Ee, A(f(/65 0Xl _LB|uX|v MzHDtt s@F8=FKovF= +)\2!})j+A Ytag@NYt( D,k`o RR$cR00-?: k,3,Gk fOC (L:gmV. v&MrHr&melk% &p@ _9|G NWWYpDNtN# p=9J f h{5^ [|lsv|w[O ;RCHs# ?XH5s\$h ,S$ LN~` $h:/:h^?* gJke` \a9-\]le F}dP gMM.

Please login or register for full access

Register

Already registered?  Login